Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Background:
- Type 1 diabetes (T1D) occurs when the immune system attacks insulin-producing cells
(beta cells) in the pancreas, resulting in their death.
- Insulin injections currently are the best method for controlling blood sugar in
individuals with T1D. However, animal studies have shown that the drugs sitagliptin and
lansoprazole can help reverse beta cell damage or develop new beta cells. In addition,
Diamyd has been shown to weaken the immune process that attacks pancreatic beta cells.
Objectives:
- To find out whether a combination treatment of sitagliptin, lansoprazole, and Diamyd
will help maintain functioning beta cells and/or cause new beta cells to form.
- To determine how the drug combination affects insulin doses and blood sugar control.
- To determine whether the drug combination affects the immune response involved in T1D.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)